eli lilly small molecule glp 1 Beyond the Needle: Lilly's Orforglipron and the GLP-1 Revolution Lilly GLP Molecular Glue

For Zepbound, nausea was also common in clinical trials

FDA's April 30, 2026 Proposal On April 30, 2026, the FDA announced a proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, finding no clinical need for outsourcing facilities to compound these drugs from bulk drug substances when FDA-approved versions are available

Front Pharm

If dietary intake is inadequate, consider supplementation, particularly if dairy products are limited in your diet

The amount of reduction of insulin dose should be determined on an individual basis based on prior diabetes control, risk of hypoglycemia and ketosis, type of GLP-1RA started, among others